Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Robinson

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
Nature Genetics|April 19, 2011
Exome sequencing identifies GRIN2A as frequently mutated in melanomaXiaomu Wei, Vijay Walia, Jimmy C Lin, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Pigment Cell & Melanoma Research|November 20, 2016
Kinase gene fusions in defined subsets of melanomaJacqueline Turner, Kasey Couts, Jamie Sheren, et al.
International Journal of Cancer|September 24, 2017
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell lineChristopher Korch, Erin M Hall, Wilhelm G Dirks, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
Nature Genetics|April 19, 2011
Exome sequencing identifies GRIN2A as frequently mutated in melanomaXiaomu Wei, Vijay Walia, Jimmy C Lin, et al.
Oncotarget|June 11, 2014
A highly recurrent RPS27 5'UTR mutation in melanomaKen Dutton-Regester, Jared J Gartner, Rafi Emmanuel, et al.
Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
Frontiers in Oncology|November 30, 2019
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma PatientsRichard P Tobin, Kimberly R Jordan, Puja Kapoor, et al.
Pigment Cell & Melanoma Research|November 20, 2016
Kinase gene fusions in defined subsets of melanomaJacqueline Turner, Kasey Couts, Jamie Sheren, et al.
International Journal of Cancer|September 24, 2017
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell lineChristopher Korch, Erin M Hall, Wilhelm G Dirks, et al.
Pageof 4